Great analysis, thank you for taking the time.
If Japan has a lower bar to pass a product to market and MSB allready has a pathway through dealings with JCR.
What is preventing them from launching CLBP and CHF in Japan and making some money to support the time it takes to complete FDA approval in the US?
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment
MSB
mesoblast limited
Add to My Watchlist
12.3%
!
$2.43
Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment, page-47
-
Top Stories
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
